Circassia Pharmaceuticals Inc.

300 S Wacker Dr Pent, Chicago, IL 60606
Pharmaceutical Companies
Business: Pharma & Medical Devices
back to directoryBack to Directory

Related Posts:

CIRCASSIA PHARMACEUTICALS, INC.: US Food and Drug Administration Approves DUAKLIR® PRESSAIR® (aclidinium/formoterol) for Patients with Chronic Obstructive Pulmonary Disease (COPD)
CIRCASSIA PHARMACEUTICALS, INC.: US Food and Drug Administration Approves DUAKLIR® PRESSAIR® (aclidinium/formoterol) for Patients with Chronic Obstructive Pulmonary Disease (COPD)

April 20, 2019

Circassia Pharmaceuticals Inc. (“Circassia” or “the Company”), today announced that the US Food and Drug Administration has approved DUAKLIR® PRESSAIR® (aclidinium bromide and formoterol fumarate) for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Read more →

Trending

BAYER: U.S. FDA Approves Addition of Overall Survival and Other Secondary Endpoint Data to NUBEQA® (darolutamide) Prescribing Information
LOCATE BIO: CognitOss Granted FDA Breakthrough Device Designation
NORTHSTAR MEDICAL RADIOISOTOPES: Announces FDA Approval for Enhanced U.S. Mo-99 Radioisotope Production Capacity
KING & SPALDING: FDA and Life Sciences Team Adds Partner in Washington
FUNCTIONAL NEUROMODULATION: Announces Breakthrough Device Designation from the U.S. FDA for Deep Brain Stimulation for Alzheimer’s Disease
ULTROMICS: Receives Fda Clearance for a First-of-kind Solution in Echocardiography to Help Clinicians Diagnose Disease

The Weekly Newsletter

Sign-up for the Weekly Newsletter from FDA Reporter.